The Situation
Our client, a major radiopharmaceutical manufacturer in the U.S., sought to determine the pricing and revenue opportunity for a pre-commercial asset across a range of potential indications. Additionally, they needed to understand the access challenges associated with the launch, both within the hospital systems and across insurance payers.
The Solution
EVERSANA MANAGEMENT CONSULTING began by developing a robust understanding of all four targeted indications and the current level of competition in each. Epidemiological research was conducted to better scope out the total market size.
These insights laid the foundation for our primary research with stakeholders across the radiopharmaceutical industry – including radiopharmacists, radiology benefit managers, and a wide range of oncologists and specialists operating within the selected indications. These interviews returned inputs into our market model, such as diagnosis rates and timing, expected prescribing, and competitive considerations.
Ultimately, the findings were consolidated into a commercial forecast model, which projected out potential revenue per indication over time while accounting for access variables – such as pricing restrictions, limitations to access for certain patient populations, and public policy.
The Results
EVERSANA MANAGEMENT CONSULTING’s work informed the investment strategy for this asset moving forward. Our client used the output of our analysis to determine which indications to continue pursuing with additional clinical trials, allowing them to narrow their scope and apply their resources to the targets with the highest likelihood of commercial success.